Sara Lodi
Profiles

Sara Lodi, PhD

Associate Professor, Biostatistics - Boston University School of Public Health

Biography

Sara Lodi is an Associate Professor of Biostatistics at the Boston University School of Public Heath. She obtained her PhD in Medical Statistics at the London School of Hygiene and Tropical Medicine in 2009, UK. Her research focuses on causal inference methods for observational studies using big data, methods for causal inference to improve the statistical analysis of clinical trials, and the reconciliation of results from clinical trials and observational studies. She leads cutting edge research that focuses on the translation of methodologic advancements in causal inference into actionable findings for real world public health research questions, mainly in the areas of infectious diseases (HIV, hepatitis C, tuberculosis) and substance use disorder. She has published many articles on behalf of large international collaborations of HIV cohorts such as CASCADE, COHERE and the HIV-CAUSAL, and HepCAUSAL collaborations. She’s been an instructor for both BS851 Applied Statistics in Clinical Trials and BS807 Applied Causal Inference in Health Research.

Education

  • London School of Hygiene & Tropical Medicine, PhD Field of Study: Statistics
  • University of Southampton, MSc Field of Study: Statistics
  • Univ of Bologna, BA Field of Study: Statistics

Classes Taught

  • SPHBS807
  • SPHBS851

Publications

  • Published on 3/19/2025

    Lodi S, Yan S, Bovell-Ammon B, Christine PJ, Hsu HE, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz JM, Walley AY, Larochelle MR. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone on treatment interruption: Comparing findings from a reanalysis of the X:BOT RCT and harmonized target trial emulation using population-based observational data. Addiction. 2025 Mar 19. PMID: 40104887.

    Read At: PubMed
  • Published on 2/19/2025

    Chalouni M, Van Santen DK, Berenguer J, Jarrin I, Miro JM, Klein MB, Young J, Torgersen J, Rentsch CT, Gill MJ, Epstein RL, Linas B, Zangerle R, Surial B, Rauch A, Touloumi G, Papadopoulos A, Wittkop L, Van Der Valk M, Boyd A, Monforte AD, Puoti M, Logan RW, Rein SM, Hernán MA, Lodi S. Time to direct-acting antivirals initiation and liver-related events in people with HIV and Hepatitis C virus. AIDS. 2025 Feb 19. PMID: 39970192.

    Read At: PubMed
  • Published on 1/8/2025

    Muyindike WR, Fatch R, Lodi S, Emenyonu NI, Kekibiina A, Adong J, Beesiga B, Marson K, Thirumurthy H, McDonell MG, Kamya MR, Chamie G, Hahn JA. Alcohol use and HIV suppression after completion of financial incentives for alcohol abstinence and isoniazid adherence: a randomized controlled trial. EClinicalMedicine. 2025 Feb; 80:103045. PMID: 39867970.

    Read At: PubMed
  • Published on 12/17/2024

    Biondi BE, Munroe S, Lavarin C, Curtis MR, Buzzee B, Lodi S, Epstein RL. Racial and Ethnic Disparities in Hepatitis C Care in Reproductive-Aged Women With Opioid Use Disorder. Clin Infect Dis. 2024 Dec 17; 79(6):1428-1436. PMID: 39356149.

    Read At: PubMed
  • Published on 8/5/2024

    Weinstein ZM, Magane KM, Lodi S, Ventura AS, Bazzi AR, Blodgett J, Fielman S, Davoust M, Shea MG, Chen CA, Cheng A, Theisen J, Blakemore S, Saitz R. The Impact of COVID-19 on Substance Use and Related Consequences Among Patients in Office-based Opioid Use Disorder Treatment. J Addict Med. 2025 Jan-Feb 01; 19(1):12-19. PMID: 39101572.

    Read At: PubMed
  • Published on 4/24/2024

    Idrisov B, Van Draanen J, Lodi S, Lunze K, Kimmel SD, Quinn EK, Truong V, Blokhina E, Gnatienko N, Krupitsky E, Samet JH, Williams EC. Socioeconomic Status and CD4 Count Among People with HIV Who Inject Drugs in St. Petersburg, Russia. AIDS Behav. 2024 Jul; 28(7):2239-2246. PMID: 38658481.

    Read At: PubMed
  • Published on 3/22/2024

    Christine PJ, Lodi S, Hsu HE, Bovell-Ammon B, Yan S, Bernson D, Novo P, Lee JD, Rotrosen J, Liebschutz J, Walley AY, Larochelle MR. Target trial emulation for comparative effectiveness research with observational data: Promise and challenges for studying medications for opioid use disorder. Addiction. 2024 Jul; 119(7):1313-1321. PMID: 38519819.

    Read At: PubMed
  • Published on 3/20/2024

    Tumwegamire A, Fatch R, Emenyonu NI, Lodi S, Muyindike WR, Kekibiina A, Adong J, Ngabirano C, Beesiga B, Marson K, Golabi N, Kamya M, Chamie G, Hahn JA. Association between smoking and lack of HIV virological suppression in a cross-sectional study of persons with HIV on antiretroviral therapy in Uganda. PLoS One. 2024; 19(3):e0300508. PMID: 38507431.

    Read At: PubMed
  • Published on 1/8/2024

    Sewak A, Lodi S, Li X, Shu D, Wen L, Mayer KH, Krakower DS, Young JG, Marcus JL. Causal Effects of Stochastic PrEP Interventions on HIV Incidence Among Men Who Have Sex With Men. Am J Epidemiol. 2024 Jan 08; 193(1):6-16. PMID: 37073419.

    Read At: PubMed
  • Published on 12/1/2023

    Chamie G, Hahn JA, Kekibiina A, Emenyonu NI, Beesiga B, Marson K, Fatch R, Lodi S, Adong J, Thirumurthy H, McDonell MG, Gandhi M, Bryant K, Havlir DV, Kamya MR, Muyindike WR. Financial incentives for reduced alcohol use and increased isoniazid adherence during tuberculosis preventive therapy among people with HIV in Uganda: an open-label, factorial randomised controlled trial. Lancet Glob Health. 2023 Dec; 11(12):e1899-e1910. PMID: 37973340.

    Read At: PubMed

News & In the Media